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Spironolactone and Colitis: Increased Mortality in
Rodents and in Humans
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Brenda W. Gillespie, PhD,‡ and Peter D.R. Higgins, MD, PhD, MSc(CRDSA)*
Background: Crohn’s disease causes intestinal inﬂammation leading to intestinal ﬁbrosis. Spironolactone is an antiﬁbrotic medication com-
monly used in heart failure to reduce mortality. We examined whether spironolactone is antiﬁbrotic in the context of intestinal inﬂammation.
Methods: In vitro, spironolactone repressed ﬁbrogenesis in transforming growth factor beta (TGF-b)-stimulated human colonic myoﬁbroblasts.
However, spironolactone therapy signiﬁcantly increased mortality in two rodent models of inﬂammation-induced intestinal ﬁbrosis, suggesting
spironolactone could be harmful during intestinal inﬂammation. Since inﬂammatory bowel disease (IBD) patients rarely receive spironolactone
therapy, we examined whether spironolactone use was associated with mortality in a common cause of inﬂammatory colitis, Clostridium difﬁcile
infection (CDI).
Results: Spironolactone use during CDI infection was associated with increased mortality in a retrospective cohort of 4008 inpatients (15.9%
vs. 9.1%, n ¼ 390 deaths, P < 0.0001). In patients without liver disease, the adjusted odds ratio (OR) for inpatient mortality associated with 80
mg spironolactone was 1.99 (95% conﬁdence interval [CI]: 1.51–2.63) In contrast to the main effect of spironolactone mortality, multivariate
modeling revealed a protective interaction between liver disease and spironolactone dose. The adjusted OR for mortality after CDI was 1.96
(95% CI: 1.50–2.55) for patients without liver disease on spironolactone vs. 1.28 (95% CI: 0.82–2.00) for patients with liver disease on spirono-
lactone when compared to a reference group without liver disease or spironolactone use.
Conclusions: We propose that discontinuation of spironolactone in patients without liver disease during CDI could reduce hospital mortality by
2-fold, potentially reducing mortality from CDI by 35,000 patients annually across Europe and the U.S.
(Inﬂamm Bowel Dis 2012;18:1315–1324)
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T he renin-angiotensin-aldosterone system (RAAS) hasbeen implicated in ﬁbrosis of multiple organs including
heart, liver, pancreas, and kidney.1–3 Spironolactone
(SPIR), a competitive aldosterone receptor antagonist, is a
potent antiﬁbrotic, improves the survival of congestive
heart failure patients, and is protective in several rodent
models of organ ﬁbrosis.4–7
Crohn’s disease (CD) frequently produces intestinal
ﬁbrosis and strictures requiring surgical intervention.8,9
Current therapies control inﬂammation and improve symp-
toms, yet do not alter the development of intestinal ﬁbrosis
and the natural history of CD.10 Intestinal wound healing is
mediated by myoﬁbroblasts, which are postulated to be the
major contributors to intestinal ﬁbrosis.11 Myoﬁbroblasts
are characterized by expression of a-smooth muscle actin
(aSMA) and are activated by transforming growth factor-
beta1 (TGF-b) in ﬁbrotic diseases.12 Angiotensin II stimu-
lates TGF-b in cardiac myoﬁbroblasts, therefore we
hypothesized that downstream aldosterone blockade of this
signaling should prevent TGF-b-induced ﬁbrosis in vitro
and in vivo.
We investigated whether SPIR reduces intestinal
ﬁbrosis in an in vitro colonic myoﬁbroblast model and in
two rodent models of intestinal ﬁbrosis. We determined
that SPIR is antiﬁbrotic in vitro. Paradoxically, in two dif-
ferent rodent colitis models, SPIR therapy during intestinal
inﬂammation produced rapid and signiﬁcant mortality. To
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evaluate the clinical relevance of our rodent mortality
results, we considered evaluating the effect of SPIR on
mortality of inﬂammatory bowel disease (IBD) patients
with active inﬂammation, but SPIR use is rare in patients
with IBD. As an alternative, we examined the mortality
associated with SPIR use in an easily identiﬁable and com-
mon source of human colonic inﬂammation, Clostridium
difﬁcile infection (CDI). We performed a multivariate
logistic regression in a retrospective cohort of inpatients
with CDI to evaluate the effect of SPIR use on CDI
mortality.
MATERIALS AND METHODS
In Vitro Model Reagents
Human recombinant TGF-b1 was obtained from R&D
Systems (Minneapolis, MN). SPIR and canrenoic acid were
purchased from Sigma Aldrich (St. Louis, MO). Enalprilat
was acquired from Hopsira (Lake Forest, IL). Eplereone was
purchased from Tocris (Ellisville, MO). Losartan was obtained
from Merck (Whitehouse Station, NJ), and aliskiren from
Novartis (East Hanover, NJ).
In Vitro Myofibroblast Culture Methods
Early passage (3–12) colonic human ﬁbroblast CCD-
18Co cells (CRL-1459 from American Type Culture Collec-
tion [ATCC], Manassas, VA) were cultured in alpha-MEM
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bo-
vine serum and subcultured weekly. For in vitro experiments,
cells were plated at 30%–40% conﬂuence and serum-starved
prior to treatment with TGF-b and other compounds. To stim-
ulate a ﬁbrotic phenotype, CCD-18co cells at 30%–40% con-
ﬂuence were serum-starved for 24 hours prior to treatment
with 1 ng/mL TGF-b or 1 ng/mL TGF-b and 100 lM SPIR or
1 mM canrenone for 48 hours. In the RAAS inhibitor experi-
ments, CCD-18co cells were stimulated with 1 ng/mL TGF-b
to which either 50 lM aliskiren, 100 nM enalprilat, 10 lM
losartan, or 50 lM eplerenone was added. Cells were har-
vested after 48 hours.
Protein Expression
Total cellular lysates were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as
previously described.13 aSMA protein was detected with a
mouse monoclonal antibody to human aSMA protein (Sigma).
GAPDH protein expression was used as a loading control
using a mouse antibody to GAPDH (Chemicon, Temecula,
CA). After application and washing of the primary antibodies,
membranes were incubated with a horseradish peroxidase
(HRP)-conjugated antibody to mouse immunoglobulin G (IgG)
(Invitrogen, Carlsbad, CA) and developed using the Pierce
Dura detection system (Rockford, IL). The resulting auto-
radiographs were scanned and the images were quantitated
using the ImageJ analysis software (available at http://rsbweb.
nih.gov/ij/).
Gene Expression Studies
RNA from CCD-18co cells was extracted using the
RNeasy kit (Qiagen, Valencia, CA). cDNA was generated by
reverse transcription of 2 lg of total RNA using the Super-
script First Strand RT kit (Invitrogen). Quantitative real-time
polymerase chain reaction (PCR) was performed for Acta2,
Col1a1, Ctgf, and Gapdh with the TaqMan gene expression
assays (ABI, Foster City, CA) on a Stratagene Mx3000P real-
time PCR system (La Jolla, CA). Gene expression was nor-
malized to Gapdh as the endogenous control and fold-changes
(RQ) relative to uninfected controls (no Tx) were calculated
using the DDCt-method.14
Rodent Models
Chronic colitis and subsequent ﬁbrosis was induced
using the rat trinitrobenzene sulfonic acid (TNBS) enema
model as previously described.15 Then 0.5, 2.5, 10, or 20 mg/
kg/day SPIR was administered twice daily by oral gavage.
Control animals received vehicle twice daily orally.
In the mouse colitis and intestinal ﬁbrosis model, mice
were infected with Salmonella typhimurium as previously
described.16 Brieﬂy, female 8–12-week-old 129S1/SvImJ mice
(Jackson Laboratories, Bar Harbor, ME) were divided into two
groups. Half the animals received regular rodent chow, the
other half received a custom rodent chow containing 2.78 g
SPIR per kg (Harlan Teklad, Madison, WI). After 1 week,
half of the animals in either the standard chow or SPIR-sup-
plemented chow groups received 20 mg of streptomycin in 0.1
M Hank’s balanced salt solution (HBSS) by oral gavage 24
hours prior to oral infection with 3  106 colony-forming
units (CFU) of S. typhimurium strain SL1344 in 100 lL 0.1 M
HEPES (pH ¼ 8.0). Uninfected animals received streptomycin
and HEPES on the same schedule as the infected groups.
Given the 100% mortality in the S. typhimurium/SPIR group,
the uninfected SPIR group was subsequently challenged at day
16 of the 21-day experiment with S. typhimurium as described
above. Surviving mice were euthanized at 21 days post-S.
typhimurium infection. Mice were monitored for weight loss/
gain, general appearance, and health. All animal experiments
were conducted with the approval and oversight of the Univer-
sity of Michigan UCUCA (University Committee on Use and
Care of Animals).
Retrospective C. difficile Colitis Study Design
A retrospective cohort of inpatients with a discharge di-
agnosis of CDI at the University of Michigan Hospital, Ann
Arbor, MI was reviewed with Institutional Review Board ap-
proval. The consent of participants to review their medical
records was waived for this protocol, as the large number of
subjects made consent impractical and the risks to subjects
were minimal. The electronic medical system was queried for
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all inpatients older than 18 years of age with a discharge diag-
nosis of CDI from January 1, 2000 through December 31,
2009. Demographics, labs, discharge diagnoses, and other per-
tinent data were abstracted electronically. To determine SPIR
dosing, a manual chart review was performed, with the highest
in-hospital dose used for modeling. Patients on eplerenone
therapy were excluded due to small sample size (n ¼ 4). Deﬁ-
nitions of heart failure and liver disease as well as descriptions
of methods of laboratory value abstraction are detailed in the
Supporting Methods. Selection of the patient sample popula-
tion for modeling is detailed in Figure 1.
Statistical Methods
The descriptive statistics are reported as means 6 stand-
ard deviation (SD) or percentages. Comparisons between the
SPIR users and nonusers were made by Student’s t-test for
quantitative variables and chi-square tests for categorical vari-
ables. Single predictor odds ratios (ORs) were calculated for
inpatient mortality using the LOGISTIC procedure in SAS 9.2
(Cary, NC). A multivariate model of inpatient mortality was
chosen using the best subset selection method in SAS while
maintaining SPIR dose, liver disease, and heart failure in the
model. As 18.6% of patients were hospitalized more than
once, the effect of hospitalization on mortality was investi-
gated and mortality was found to be greater in the ﬁrst two
hospitalizations. Therefore, the single predictor and multivari-
ate models were adjusted for the hospitalization number for
each individual, dichotomized as 2 vs. >2 hospitalizations.
All possible two-way interactions were tested. P-values less
than 0.05 were considered statistically signiﬁcant. All tests are
two-sided.
The original Model for Endstage Liver Disease (MELD)
formula, which allows for negative values, was used.17 The
optimal functional form of SPIR dose in the multivariate
model was assessed by comparing linear to both logarithmic
and quadratic transformations using Akaike information crite-
ria (AIC) and likelihood ratio testing. Sensitivity of the model
to high doses of SPIR (>100 mg) was tested by comparing
parameter estimates in a model with and without these higher
doses. As stated in the Results, this did not change the signiﬁ-
cance of any of the parameters.
The logistic regression analysis strategy was based on a
model for discrete survival. In our case, the time axis was hos-
pitalization number, with death (yes/no) evaluated for each
hospitalization. In such discrete survival models, time is
entered as a model term. After considering continuous (linear)
versus categorical variables for hospitalization number, we
determined that using categories (2 hospitalizations vs. >2)
provided the best ﬁt. To test the robustness of our modeling
method we also performed logistic regression on a random
hospitalization for each patient. The results of this alternative




To determine whether SPIR is antiﬁbrotic in vitro,
human colonic myoﬁbroblasts (CCD-18co) were stimulated
with TGF-b to induce a ﬁbrotic phenotype characterized by
increased actin stress ﬁber accumulation, aSMA protein
expression, and increased expression of proﬁbrotic genes
including Acta2, Col1a1, and Ctgf (data not shown). SPIR
repressed TGF-b induction of aSMA protein expression in
a dose-dependent manner (Fig. 2A). SPIR repressed actin
stress ﬁber formation (data not shown). Both SPIR and its
active metabolite, canrenone, dramatically repressed TGF-
b-induced aSMA protein expression (data not shown).
SPIR repressed the expression of ﬁbrotic genes Acta2,
Col1a1, and Ctgf to levels indistinguishable from untreated
controls (Fig. 2B). Canrenone signiﬁcantly repressed Acta2
mRNA expression, but its reduction in Col1a1 and
Ctgf mRNA expression were not statistically signiﬁcant
(Fig. 2B).
Given the antiﬁbrotic effect of SPIR, we investigated
whether blocking upstream components of the RAAS
pathway (Fig. 2C) would block ﬁbrosis in vitro. In
TGF-b-stimulated myoﬁbroblasts, other RAAS inhibitors
aliskiren (renin inhibitor), enalaprilat (ACE inhibitor), and
losartan (angiotensin II type I receptor blocker [ARB])
partially repressed proﬁbrotic gene expression (Fig. 2D,E),
suggesting a role for the RAAS pathway in intestinal ﬁbrosis.
Rodent Colitis Studies
Unexpectedly, in two animal models of intestinal
inﬂammation and ﬁbrosis, treatment with SPIR caused sig-
niﬁcant and rapid mortality. In the rat TNBS chronic colitis
model, 20 mg/kg/day SPIR (10-fold lower than well-toler-
ated doses in other rat models18) produced 67% mortality
(95% conﬁdence interval [CI]: 0.046–0.68) (Fig. 3A). A
dose–response experiment in the rat TNBS model
FIGURE 1. Consolidated Standards of Reporting Trials (CONSORT)
ﬂow diagram. Selection of inpatient subjects for modeling among
patients with a discharge diagnosis of CDI. Readmissions for recur-
rent CDI within 30 days of discharge were treated as a single
admission for this analysis.
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demonstrated increased survival with decreasing SPIR
dose. Mortality was 33% at 10 mg/kg/day, and 0% at 2.5
or 0.5 mg/kg/day (Fig. 3B). However, lower doses of SPIR
did not reduce the development of ﬁbrosis, as determined
by gross pathology, histopathology, ﬁbrotic gene expres-
sion, and protein expression (aSMA) (data not shown).
FIGURE 2. Results of in vitro studies. (A) SPIR inhibits TGF-b induction of aSMA protein expression in colonic myoﬁbroblasts. A representa-
tive western blot of aSMA expression in protein extracts from CCD-18co colonic myoﬁbroblasts stimulated for 24 hours with TGF-b is
shown. Increasing amounts of SPIR from 10 lM to 100 lM reduce aSMA expression to levels comparable to unstimulated cells (no Tx).
GAPDH expression serves as the loading control for the amount of protein. (B) Treatment of TGF-b stimulated CCD-18co cells with SPIR
represses expression of Acta2, Col1a1, and Ctgf. A metabolite of SPIR, canrenone (CAN), partially represses proﬁbrotic gene expression. (C)
The role of the RAAS pathway in ﬁbrosis and the relationship of pathway inhibitors. (D) Inhibitors of the RAAS pathway aliskiren (ALK), ena-
laprilat (ENT), and losartan (LOR) partially repress TGF-b induction of ﬁbrotic genes with partial repression of Acta2 expression but have
minimal effect on Col1a1 expression (E). Results are from nine independent experiments. Asterisks denote statistically signiﬁcant compari-
sons between untreated control cells (no Tx) and the treatment groups. Brackets denote comparisons between TGF-b treated and other
treatment groups. *P < 0.05, ***P < 0.001.
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Similar experiments with losartan resulted in no mortality
and no improvement in ﬁbrosis (data not shown).
In the mouse S. typhimurium infection model of
intestinal ﬁbrosis, treatment with 0.7 mg/kg/day of
SPIR produced 80% mortality (95% CI: 0.69–1.00) by
day 9 of colitis compared to 20% mortality in the
S. typhimurium-infected group (Fig. 3C). No mortality
occurred in uninfected mice receiving 0.7 mg/kg/day of
SPIR. However, when the SPIR-treated cohort was later
challenged with S. typhimurium, 100% mortality occurred
by day 5 postinfection.
Retrospective Study of C. difficile Colitis Clinical
Outcomes
To determine whether SPIR use was associated with
increased mortality in humans with intestinal inﬂammation,
we identiﬁed a total of 4008 inpatients with a discharge di-
agnosis of CDI in University of Michigan Hospital admis-
sions from January 1, 2000 through December 31, 2009.
These 4008 patients accounted for a total of 5166 CDI-
associated hospitalizations in that 10-year period. There
were 352 patients on SPIR during at least one hospitaliza-
tion; these patients were hospitalized 391 times. The aver-
age time between hospitalizations for SPIR users was not
signiﬁcantly different from nonusers, while the average
number of hospitalizations for the two groups did differ
(1.4 vs. 1.3, P ¼ 0.02, n ¼ 4,008) (Table 1). In patients on
SPIR therapy, the average dose was 79.9 mg (671.5). The
average age, gender ratio, and race did not differ between
SPIR users and nonusers.
As expected, the group on SPIR therapy had signiﬁ-
cantly more patients with a diagnosis of heart failure
(38.9% vs. 15.0%, P < 0.0001) and liver disease (42.9%
vs. 7.5%, P < 0.0001) compared to nonusers of SPIR. The
mortality in those patients with heart failure was 77 of 686
(11.2%), in those with liver disease was 71 of 424
(16.7%), and in patients with neither heart failure nor liver
disease was 242 of 2898 (8.4%). The majority of patients
taking SPIR without a history of heart failure or liver dis-
ease were doing so due to hypertension or evidence of
edema.
Laboratory values affected by heart or liver dysfunc-
tion (creatinine, sodium, international normalized ratio
[INR], total bilirubin, potassium, albumin) were signiﬁ-
cantly different between users and nonusers of SPIR (Table
1), and were used as proxies for disease severity in a pre-
dictive model. Bilirubin and INR were higher in the SPIR
group while sodium, albumin, and creatinine were lower.
Discharge day potassium was higher in the SPIR group.
The MELD17 score showed a signiﬁcant difference
between the two groups, while there was no signiﬁcant dif-
ference in Charlson-Deyo comorbidity index.19,20 The clini-
cal outcomes in the two groups demonstrated signiﬁcant
differences, with longer length of stay, higher mortality,
and higher costs per hospitalization in the SPIR users.
Figure 4 shows the single predictor ORs for inpatient
mortality in all patients after adjustment for hospitalization
number. In this analysis (n ¼ 5166, patients on SPIR had
1.84 [95% CI: 1.34–2.53] times the odds of inpatient mor-
tality of those not on the medication). For each additional
FIGURE 3. Results of rodent colitis studies. (A) Increased mortality
in rats with chronic TNBS colitis treated with SPIR. Kaplan–Meier
mortality estimates of rats with chronic TNBS and 20 mg/kg/day
SPIR (TNBSþSP) compared to no mortality with TNBS alone and in
untreated rats (no Tx). Data are from three rats per experimental
group. (B) Increased mortality in rats with chronic TNBS colitis
treated with SPIR is dose-dependent. The Kaplan–Meier curve dem-
onstrates increased mortality in rats with chronic TNBS colitis
treated with doses of 10 or 20 mg/kg/day SPIR (TþSP 20, TþSP 10)
compared to low doses of SPIR (TþSP 0.5, TþSP 2.5), TNBS alone,
or rats with no treatment (no Tx). Data are from three rats per ex-
perimental group. (C) SPIR treatment increases mortality in the S.
typhimurium mouse model of colitis. Mortality occurred in mice
with S. typhimurium-induced colitis treated with 0.7 mg/kg/day
SPIR (SPþSt), compared with mice infected with S. typhimurium
without SPIR (St), uninfected mice (no Tx), or mice receiving 0.7
mg/kg/day SPIR alone (SP). Uninfected mice which received SPIR
treatment over 15 days had 0% mortality until subsequent S. typhi-
murium induction of colitis (SP!SP þ St) at day 16 (vertical arrow),
which produced 100% mortality by day 5 postinfection. Data are
from ﬁve mice per experimental group.
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25 mg of SPIR dose, the OR for mortality was increased
by 13% (95% CI: 6%–20%). Liver disease, higher MELD
scores, and heart failure were associated with higher inpa-
tient mortality, while Charlson-Deyo scores were not.
ACE-I (angiotensin converting enzyme inhibitor) and ARB
use were both associated with decreased mortality.
These predictors were combined in a multivariate
logistic regression model (n ¼ 4415) to predict inpatient
mortality (Fig. 5A). We found that SPIR use remained a
signiﬁcant predictor of mortality, and found a statistically
signiﬁcant interaction between SPIR dose and liver disease,
described below. Testing the other univariate predictors,
we found that blood urea nitrogen (BUN), total bilirubin,
albumin, and use of ACE-I and ARB medications were sig-
niﬁcant contributors to our model of inpatient mortality.
No signiﬁcant interaction between heart failure and
SPIR use was found. In all, 4415 hospitalizations without
missing values were included in this model. Hospitalization
number was also included for each individual in the model;
patients were more likely to die during one of the ﬁrst two
hospitalizations than in subsequent hospitalizations (OR
1.52, 95% CI: 0.92–2.50, P ¼ 0.10). This model had fairly
high explanatory power, with a c statistic of 0.71. The
linear form of SPIR dosing in the model was statistically
superior to a quadratic or logarithmic transformation. The
exclusion of high doses of SPIR (>100 mg) did not
substantially alter the model.
Because of the interaction between liver disease and
SPIR, patients with liver disease had a (nonsigniﬁcant) pro-
tective effect from SPIR of 29% (OR 0.71, 95% CI: 0.47–
1.07), while patients without liver disease had signiﬁcantly
worse outcomes with SPIR. Compared to the reference
group (patients without liver disease not taking SPIR),
patients with liver disease taking the average dose of SPIR
TABLE 1. Characteristics of Patients with C. difﬁcile Colitis on Spironolactone Therapy
Characteristic
Spironolactone Therapy
(N ¼ 352) Mean (6 SD),
Mean [Range] or n (%)
No Spironolactone
Therapy (N ¼ 3656)
Mean (6 SD), Mean
[Range] or n (%) P value (N)
Age (years) 57.1 (6 14.2) 57.6 (6 17.9) 0.53
Male 181 (51.4%) 1859 (50.9%) 0.84
Race 0.29
Caucasian 282 (80.1%) 3025 (82.7%)
African-American 37 (10.5%) 369 (10.1%)
Other 33 (9.4%) 262 (7.2%)
Hospitalizations (individual) 391 4775
No. of hospitalizations per patient 1.4 [1 – 6] 1.3 [1 – 12] 0.02
Time between hospitalizations (days) 132.5 [1 – 1483] 129.2 [1 -2383] 0.90
Heart failure 137 (38.9%) 549 (15.0%) <0.0001
Liver disease 151 (42.9%) 273 (7.5%) <0.0001
Diabetes 90 (25.6%) 835 (22.8%) 0.25
Baseline measures (per hospitalization)
Sodium (mmol/L) 134.9 (6 5.6) 137.4 (6 4.8) <0.0001 (5121)
Potassium (mmol/L) 4.2 (6 0.6) 4.1 (6 0.5) 0.0004 (4582)
Creatinine (mg/dL) 1.3 (6 0.7) 1.5 (6 1.6) <0.0001 (5118)
BUN (mg/dL) 27.5 (6 18.3) 25.3 (6 20.4) 0.03 (5119)
INR 1.6 (6 1.0) 1.4 (6 1.0) 0.007 (3763)
Albumin (g/dL) 3.1 (6 0.7) 3.1 (6 0.7) <0.0001 (4432)
Total bilirubin (mg/dL) 3.1 (6 5.3) 1.3 (6 3.5) <0.0001 (4479)
MELD 6.6 (6 9.0) 2.5 (6 10.1) <0.0001 (3416)
Charlson-Deyo Comorbidity Index 4.1 (6 2.7) 3.9 (6 2.7) 0.25 (3741)
Outcomes
Mortality (by individual) 56 (15.9%) 334 (9.1%) <0.0001
Mortality (by hospitalization) 49 (12.5%) 341 (7.1%) 0.0001
Length of each hospitalization (days) 25.0 [1 – 171] 17.1 [1- 851] <0.0001
Cost per hospitalization (in $1000’s) 197.9 [0 – 2489.4] 110.4 [0 – 6388.0] <0.0001
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(80 mg) had an adjusted OR for inpatient mortality of 1.07
(95% CI: 0.70–1.64). In patients without liver disease, the
adjusted OR for inpatient mortality associated with 80 mg
SPIR was 1.99 (95% CI: 1.51–2.63) (Fig. 5A) compared to
the reference group. We show the direct effects of this
interaction term on mortality in Figure 5B, where the prob-
abilities of inpatient mortality in patients with liver disease,
heart failure, and with neither of these comorbidities are illus-
trated. To show the dose–response effect, we modeled the
predicted probability of inpatient mortality for each disease
state for patients on high-dose SPIR, low-dose SPIR, and
those not taking the drug. Predicted probabilities are based
on the average values of total bilirubin, albumin, and BUN,
ACE-I/ARB use, and hospitalization number 2. Patients
with liver disease had a lower probability of inpatient mortal-
ity if they were using SPIR. In contrast, in patients with heart
failure, who are typically on lower doses of SPIR, we demon-
strate an increase in inpatient mortality with SPIR use. The
patients without liver disease or heart failure were on higher
average doses of SPIR, and this is reﬂected in a signiﬁcantly
increased risk of inpatient mortality.
DISCUSSION
The antiﬁbrotic effects of aldosterone antagonists
have been demonstrated in multiple organs. Clinically, the
use of SPIR has a signiﬁcant survival beneﬁt in heart fail-
ure, but the effect of SPIR on intestinal ﬁbrosis is
unknown. In this study we found that SPIR represses
ﬁbrotic protein expression and the expression of proﬁbrotic
genes in intestinal myoﬁbroblasts. However, we found that
SPIR intervention during inﬂammatory colitis signiﬁcantly
increased mortality in two rodent models of inﬂammatory
intestinal ﬁbrosis. We extended this ﬁnding to patients in a
retrospective cohort study of clinical outcomes at a large
tertiary center and found that SPIR use in patients with
CDI was associated with an increased mortality rate in
patients without liver disease, even after adjusting for
comorbidities and disease severity.
SPIR is absorbed through the gut mucosa and metab-
olized in the liver. While the pharmacokinetics of SPIR
metabolism are complex due to the large number of active
metabolites generated, in patients with liver disease
impaired SPIR metabolism has been reported.21–23 Altered
hepatic SPIR metabolism may account for the differential
mortality outcomes of liver disease compared to nonliver
disease patients.
Our ﬁnal model includes high blood urea nitrogen as
a predictor of mortality, which may be a marker of dehy-
dration and therefore severity of CDI. Based on our in
vitro results, we would anticipate that ACE inhibitors and
ARBs, as inhibitors of the RAAS, would have effects sim-
ilar to SPIR, but this was not the case. The protective
effect of ACE inhibitors and ARBs suggests that SPIR
may have a distinct mechanism that is associated with
mortality in the setting of CDI. Our ﬁndings are supported
by a recent retrospective study which demonstrated ACEI/
ARB use during CDI was associated with decreased
mortality.24
While we cannot infer causality with a retrospective
study, several aspects of our study provide compelling
FIGURE 4. Single predictor odds ratios for inpatient mortality in patients with C. difﬁcile colitis. For each predictor, the odds ratio from a
logistic model for inpatient mortality was adjusted for hospitalization number (2 vs. >2) and is presented with 95% CIs. A vertical dashed
line at 1 represents the point of no effect.
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evidence for the combination of SPIR and intestinal
inﬂammation affecting mortality. In our rodent models,
we did not observe adverse outcomes when animals were
treated with SPIR alone, or when colitis was induced
without SPIR. In addition, we observed a dose-dependent
increased mortality in the rodent models. Clinically, we
observed a dose-dependent effect of SPIR on inpatient
mortality which was maintained despite adjusting for
important covariates associated with SPIR usage and
mortality.
Although entirely speculative, SPIR therapy in the
context of epithelial barrier loss could act synergistically
with the C. difﬁcile toxins to increase inﬂammation severity
and mortality. During CDI, toxin A disrupts the epithelial
barrier from the apical side, potentiating toxin B access to
receptors in the basolateral side.25 While toxin B is
FIGURE 5. Adjusted odds ratios for and predicted probabilities of inpatient mortality in patients with C. difﬁcile colitis. (A) The adjusted ORs
for inpatient mortality in a multivariate model containing SPIR, liver disease, heart failure, the interaction between SPIR and liver disease,
ACE-I use, ARB use, total bilirubin, albumin, BUN, and hospitalization number (2 vs. >2). The OR for liver diseases with and without SPIR
and the OR of liver disease with SPIR are compared to patients without liver disease not taking SPIR (Reference group). (B) The predicted
probability (with 95% CI) of inpatient mortality in patients with liver disease, heart failure, and neither liver disease nor heart failure while
using three possible doses of SPIR for that disease state. For each disease state the average total bilirubin, albumin, and BUN were used in
conjunction with the proportion of patients on ACE-I and ARB medications. Details for each disease state are in the Supporting Materials.
In all groups the probability is shown for hospitalization number 2. This demonstrates that SPIR use is associated with increased mortality
in patients without liver disease.
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essential for virulence, toxin B alone does not cause symp-
toms unless mucosal damage has occurred.26–28 Toxin B,
via a Rho/Rac signaling pathway, induces inducible nitric
oxide synthase (iNOS), subsequent loss of epithelial barrier
function, increased permeability, increased chloride secre-
tion, and diarrhea.29 In our rodent colitis models SPIR had
no effect in rodents with intact colons, but produced rapid
mortality after damage to the intestinal epithelial barrier.
To our knowledge, SPIR has not been reported to
disrupt the epithelial barrier, but SPIR does affect iNOS
signaling. In the heart, SPIR induces iNOS while aldo-
sterone represses iNOS, suggesting a functional link
between the iNOS pathway and SPIR signaling.30 In
contrast to SPIR, ACE inhibitors (captopril) and ARBs
(candesartan, losartan) have been reported to reduce
iNOS expression in the heart and kidney.31–33 We postu-
late that during the loss of barrier integrity caused by
colonic inﬂammation, SPIR can act synergistically with
C. difﬁcile toxin B by further inducing iNOS, contribut-
ing to additional barrier disruption and increasing disease
severity and mortality.
CONCLUSIONS
Clostridium difﬁcile is a major source of hospital-
acquired infections.34 Based on our results in the rodent
models and the human cohort study, we propose that tem-
porary discontinuation of SPIR in patients during CDI
without liver disease could signiﬁcantly reduce mortality in
the more than 2.7 million hospitalized patients in the U.S.
with CDI each year.35 We estimate that a similar number
of patients across Europe are hospitalized with CDI.
Assuming that 8.9% of CDI patients in Europe and the US
are on SPIR therapy (as in our sample), a 2-fold reduction
in mortality among SPIR users with CDI would save an
estimated 35,000 lives annually across Europe and the U.S.
Prospective clinical studies are needed to determine
whether temporary discontinuation of SPIR in patients with
CDI changes clinical outcomes.
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